Journal of Cachexia, Sarcopenia and Muscle
Overview
The Journal of Cachexia, Sarcopenia and Muscle is a peer-reviewed publication dedicated to advancing the understanding and management of cachexia, sarcopenia, and muscle wasting disorders. It provides a platform for researchers and clinicians to share cutting-edge research, clinical trials, and innovative therapies aimed at improving the quality of life for individuals affected by these conditions.
Details
Details
Abbr.
J Cachexia Sarcopenia Muscle
Start
2010
End
Continuing
Frequency
Quarterly
p-ISSN
2190-5991
e-ISSN
2190-6009
Country
Germany
Language
English
Metrics
Metrics
h-index / Ranks: 3121
100
SJR / Ranks: 676
2816
CiteScore / Ranks: 804
13.00
JIF / Ranks: 563
8.9
Recent Articles
1.
Guo L, Han M, Xu J, Zhou W, Shi H, Chen S, et al.
J Cachexia Sarcopenia Muscle
. 2025 Mar;
16(2):e13752.
PMID: 40079370
Background: Cell-cell crosstalk between myogenic, adipogenic and immune cells in skeletal muscle to regulate energy metabolism and lipid deposition has received considerable attention. The specific mechanisms of interaction between the...
2.
Dajani O, Philips I, Storkson E, Balstad T, Brown L, Bye A, et al.
J Cachexia Sarcopenia Muscle
. 2025 Mar;
16(2):e13756.
PMID: 40065459
Background: In patients receiving anti-cancer treatment, cachexia results in poorer oncological outcomes. However, there is limited understanding and no systematic review of oncological endpoints in cancer cachexia (CC) trials. This...
3.
Lu Q, Sun H, Zhou K, Su J, Meng X, Chen G, et al.
J Cachexia Sarcopenia Muscle
. 2025 Mar;
16(2):e13761.
PMID: 40052435
Background: A significant increase in mitochondrial fatty acid oxidation (FAO) is now increasingly recognized as one of the metabolic alterations in diabetic cardiomyopathy (DCM). However, the molecular mechanisms underlying mitochondrial...
4.
Yu J, Ahn H, Han K, Song W, Sung H, Jeon H, et al.
J Cachexia Sarcopenia Muscle
. 2025 Mar;
16(2):e13758.
PMID: 40052383
Background: Treatment for metastatic renal cell carcinoma (mRCC) has shifted from tyrosine kinase inhibitor (TKI) therapy to immune checkpoint inhibitor (ICI)-based therapy, improving outcomes but with variable individual responses. This...
5.
Aktas A, Kadakia K, Waldman J, Walsh D
J Cachexia Sarcopenia Muscle
. 2025 Mar;
16(2):e13754.
PMID: 40049702
Accurate toxicity reporting in cancer clinical trials is necessary to promote regulatory decision making. Up to 85% of those with some cancers (e.g., oesophagus, head and neck, and pancreas) experience...
6.
Reza M, Qiu C, Lin X, Su K, Liu A, Zhang X, et al.
J Cachexia Sarcopenia Muscle
. 2025 Mar;
16(2):e13661.
PMID: 40045692
Background: Sarcopenia presents a pressing public health concern due to its association with age-related muscle mass decline, strength loss and reduced physical performance, particularly in the growing older population. Given...
7.
Silva P, Cipriano Jr G
J Cachexia Sarcopenia Muscle
. 2025 Mar;
16(2):e13767.
PMID: 40045555
No abstract available.
8.
Takagi S, Satake S, Sugimoto K, Kuzuya M, Akishita M, Arai H, et al.
J Cachexia Sarcopenia Muscle
. 2025 Mar;
16(2):e13770.
PMID: 40042192
No abstract available.
9.
Rahmati M, Lee H, Lee H, Park J, Vithran D, Li Y, et al.
J Cachexia Sarcopenia Muscle
. 2025 Mar;
16(2):e13772.
PMID: 40042073
Background: Numerous studies support the association of exercise training, physical activity (PA) and sedentary behaviour (SB) with both mortality and morbidity outcomes. The results across studies have been inconsistent, and...
10.
Setoyama Y, Honda T, Ninomiya T
J Cachexia Sarcopenia Muscle
. 2025 Mar;
16(2):e13764.
PMID: 40042054
No abstract available.